Intuitive Surgical, Inc.
ISRG · Nasdaq
ISRG · Nasdaq
Intuitive Surgical sells robotic-surgery technology, centered on its da Vinci platform, to support procedures across urology, general surgery and newer specialties. It makes money through upfront system placements and recurring sales tied to instruments, accessories and related services, although the supplied figures do not quantify the contribution of each category. Its customers are healthcare providers and surgical teams using robotic platforms. The company generated $10.1 billion of revenue and $2.9 billion of net income in FY2025, up from $8.4 billion and $2.3 billion, respectively, in FY2024, indicating a large and growing commercial base.
Intuitive Surgical rose $6.46, or 1.79%, from $361.80 to $368.26 over the supplied week. The stock first fell sharply to $353.10 on July 29 and $352.97 on July 30, then held near $353.33 on July 31 before jumping $22.08 to $375.41 on August 3. It gave back $7.15 of Monday’s gain on August 4, leaving it above the starting level but well below the weekly high. The supplied evidence does not identify a company-specific announcement or earnings release driving those reversals. Investor-attention and robotic-surgery expansion articles were available, but no timing links them to the trading days. The move therefore appears to have occurred without a documented company-specific catalyst.
